Combination therapy with metformin and glibenclamide and insulin therapy were both significantly more frequent among patients with previous hypoglycemic episodes, whereas single therapy with metformin was more prevalent among T2DM patients without previous hypoglycemic episodes. This evidence concerns the gene INS and type 2 diabetes mellitus.